New imaging study aims to stop blindness from misdiagnosed artery inflammation
NCT ID NCT07206238
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 29 times
Summary
This study looks at two conditions that can cause sudden vision loss: giant cell arteritis (GCA), a blood vessel inflammation that needs urgent treatment, and NAION, a similar condition that does not benefit from that treatment. Researchers will use special PET/MRI scans and eye imaging in 122 adults to find signs of inflammation around the eye's blood vessels. The goal is to better tell these conditions apart, so GCA patients get the right treatment quickly and NAION patients avoid unnecessary side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet - Glostrup
RECRUITINGGlostrup Municipality, 2600, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.